Board Meeting Details

The Board of Directors meeting was held on July 21, 2026, commencing at 15:00 PM and concluding at 15:40 PM. The board approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.

Standalone Financial Results (Amount in ₹ millions)

Income Statement Highlights:

  • Revenue from operations: ₹403.96 million for Q1 FY27, compared to ₹343.24 million in Q1 FY26 (17.7% YoY increase) and ₹354.05 million in Q4 FY26
  • Other income: ₹19.18 million for Q1 FY27, compared to ₹25.92 million in Q1 FY26 and ₹10.62 million in Q4 FY26
  • Total income: ₹423.14 million for Q1 FY27, compared to ₹369.16 million in Q1 FY26 and ₹364.67 million in Q4 FY26
  • Purchase of stock-in-trade: ₹203.71 million for Q1 FY27
  • Changes in inventories: ₹67.57 million increase for Q1 FY27, compared to ₹(10.26) million decrease in Q1 FY26
  • Employee benefits expense: ₹40.27 million for Q1 FY27
  • Finance costs: ₹1.77 million for Q1 FY27
  • Depreciation and amortization: ₹5.66 million for Q1 FY27
  • Fair value changes and net loss on investments: ₹0.70 million loss for Q1 FY27, compared to ₹83.37 million loss in Q4 FY26
  • Other expenses: ₹67.27 million for Q1 FY27
  • Profit before tax: ₹36.19 million for Q1 FY27, compared to ₹8.33 million in Q1 FY26 and ₹(61.52) million loss in Q4 FY26
  • Tax expense: ₹11.87 million for Q1 FY27 (Current tax: ₹1.50 million, Deferred tax: ₹10.37 million)
  • Profit after tax: ₹24.32 million for Q1 FY27, compared to ₹5.52 million in Q1 FY26 and ₹(66.25) million loss in Q4 FY26
  • Total comprehensive income: ₹24.32 million for Q1 FY27, compared to ₹5.52 million in Q1 FY26 and ₹(65.74) million loss in Q4 FY26

Capital Structure:

  • Paid-up equity share capital: ₹95.42 million (Face value ₹10 per share), unchanged from Q4 FY26 but reduced from ₹100.00 million in Q1 FY25
  • Earnings per share (Basic and diluted): ₹2.55 for Q1 FY27, compared to ₹0.55 in Q1 FY26 and ₹(6.95) in Q4 FY26

Consolidated Financial Results (Amount in ₹ millions)

Income Statement Highlights:

  • Revenue from operations: ₹403.43 million for Q1 FY27
  • Other income: ₹18.20 million for Q1 FY27
  • Total income: ₹421.63 million for Q1 FY27
  • Profit before tax: ₹44.33 million for Q1 FY27, compared to ₹12.31 million in Q1 FY26 and ₹(55.11) million loss in Q4 FY26
  • Profit after tax from continuing operations: ₹30.67 million for Q1 FY27, compared to ₹8.13 million in Q1 FY26 and ₹(60.92) million loss in Q4 FY26
  • Total comprehensive income: ₹30.51 million for Q1 FY27, compared to ₹8.13 million in Q1 FY26 and ₹(60.17) million loss in Q4 FY26
  • Earnings per share (Basic and diluted): ₹3.21 for Q1 FY27 from continuing operations

Notes to Financial Results

Accounting Policies:

  • Financial results prepared in accordance with Indian Accounting Standards (IND AS)
  • Company operates in single business segment: "Home healthcare and wellness products"
  • Figures for quarter ended March 31, 2026 are balancing figures between audited annual figures and published quarterly figures

Corporate Actions:

  • During previous year, company undertook buyback of equity shares through tender offer route at price of ₹330 per share
  • Buyback was funded from company's free reserves, including securities premium
  • Buyback completed during quarter ended December 31, 2025
  • Equity shares bought back have been extinguished and Capital Redemption Reserve created pursuant to Section 69 of Companies Act, 2013

Pending Merger:

  • Company has filed Scheme of Merger by Absorption whereby Nureca Technologies Private Limited (wholly owned subsidiary) will merge with the company
  • Scheme proposed with appointed date of April 1, 2025, subject to sanction of National Company Law Tribunal and other regulatory approvals
  • No accounting impact recognized in these results pending sanction of the Scheme

Review and Approval Process:

  • Results reviewed by Audit Committee and approved by Board of Directors on July 21, 2026
  • Limited review completed by Statutory Auditors (Singhi & Co.) who expressed unmodified opinion on the results

Auditor's Report Details:

  • Independent auditor's review report issued by Singhi & Co. (Firm Registration No. 302049E)
  • Review conducted in accordance with Standard on Review Engagements (SRE) 2410
  • Auditors found nothing to suggest material misstatement or non-compliance with disclosure requirements
  • Consolidated results include Nureca Limited (holding company), Nureca Technologies Private Limited (subsidiary), and Nureca INC (subsidiary incorporated in USA)
  • One subsidiary's results (revenue ₹68.19 million, net profit ₹4.26 million) reviewed by other auditor
  • Foreign subsidiary's results (net loss ₹0.25 million) not reviewed by its auditor but converted to IND AS by management